In the intent-to-treat analysis, 54% of diabetic wounds treated with the high dose of DSC127 reached 100% closure compared to 33% of patients treated with the placebo gel. The study was not powered for statistically significance, although Derma expected a 15% improvement in wound healing with the high dose of DSC127 compared to placebo. The actual 21% improvement was better than expected. [The wound-healing rate for low-dose DSC127 was 30%, below that of the placebo.]
Derma didn't provide much detail on safety other than to say the drug was well tolerated and that no significant adverse events were reported. The company expects to report further data from the DSC127 study in the second quarter.
A drug that effectively closes and heals diabetic foot ulcers can probably bring in about $200 million to $300 million a year in sales.
Vince M. asks, "I'm surprised you haven't written about Radient Pharmaceuticals (RPC) since its big move in December. What are your thoughts about Radient's cancer test? The stock has fallen back and looks more attractive at these levels, especially if the company can make millions of dollars from India."I'm late to the Radient story not for lack of interest but because I've been waiting almost a month to schedule an interview with Radient CEO Doug MacLellan to discuss the company's Onko-Sure cancer screen. MacLellan canceled one interview with me. I tried to reschedule several times through Radient's media person with no luck, so I'll move ahead. Radient is investing a lot of money into investor and media relations, which helps explain the mini stock-price bubble. Press releases are flying out the company's door filled with announcements about international distribution deals for the Onko-Sure cancer test. At the same time, MacLellan is granting interviews with a biotech stock promotions Web site claiming Onko-Sure is on the cusp of generating millions of dollars in revenue. A fine line exists between optimism and delusion, and I'm afraid MacLellan might be on the wrong side of the divide. Past performance isn't necessarily an indicator of future results, but in Radient's case, it's a damn good proxy. Onko-Sure sales for the first nine months of 2010 totaled $116,000, a 15% decrease from sales in the first nine months of 2009. Radient's loss from operations through the end of September 2010 was $6.7 million; add in losses from discontinued operations and business units Radient is trying to sell, and the total net loss was $38.4 million.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV